Key result
PCSK9 inhibitors may provide additional benefits in solid organ transplant patients by reducing LDL cholesterol and inflammation, with fewer drug interactions with immunosuppressants.
Why the study?
Dyslipidemia increases cardiovascular risk in solid organ transplant patients, but PCSK9 inhibitors remain poorly used despite comparable efficacy and fewer immunosuppressant interactions.
Do PCSK9 inhibitors improve lipid profiles and cardiovascular outcomes in solid organ transplant patients?
Do PCSK9 inhibitors improve lipid profiles and cardiovascular outcomes in solid organ transplant patients?
PCSK9 inhibitors represent an effective and safe option for managing dyslipidemia in solid organ transplant patients, potentially offering additional benefits for graft survival through anti-inflammatory pathways.
May support PCSK9 inhibitor consideration in transplant dyslipidemia; leaves open dedicated outcome trials.
Dyslipidemia is a widespread risk factor in solid organ transplant patients, due to many reasons, such as the use of immunosuppressive drugs, with a consequent increase in cardiovascular diseases in this population. PCSK9 is an enzyme mainly known for its role in altering LDL levels, consequently increasing cardiovascular risk. Monoclonal antibody PCSK9 inhibitors demonstrated remarkable efficacy in the general population in reducing LDL cholesterol levels and preventing cardiovascular disease. In transplant patients, these drugs are still poorly used, despite having comparable efficacy to the general population and giving fewer drug interactions with immunosuppressants. Furthermore, there is enough evidence that PCSK9 also plays a role in other pathways, such as inflammation, which is particularly dangerous for graft survival. In this review, the current evidence on the function of PCSK9 and the use of its inhibitors will be discussed, particularly in transplant patients, in which they may provide additional benefits.
No takes yet. Share an insight, caveat, or question.
Cuomo et al. (2022) conducted a review in Atherogenic Dyslipidemia in Solid Organ Transplant Patients. PCSK9 inhibitors was evaluated. PCSK9 inhibitors may provide additional benefits in solid organ transplant patients by reducing LDL cholesterol and inflammation, with fewer drug interactions with immunosuppressants.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: